Theralase® is currently designing and developing a new proprietary light activation platform; specifically, the TLC-3000B, to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. The TLC-3000B is expected to be completed for use by PHAC and NRC in 1Q2023.
The above results and completion of the TLC-3000B will lay the groundwork for the next phase of the CRA and TTSA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, at two world class laboratories, when exposed to the virus, which is expected to commence in 1Q2023 and be completed by 1Q2024.
From the Management Notes.
So where did this come from? We go from expecting a result from the animal testing of a Covid vaccine in Q4 2022 to something totally different.
More questions without context or answers.
Yes the phase 2 results looking even better - couldn't help but notice anitger format change on the data presentation.
BTD not applied for yet although the table suggests more than enough patients have completed their 450 day scan results.
I await the market reaction tomorrow to see what the smart money thinks